Aclaris Therapeutics (ACRS) Price & Analysis

Compare

810 Followers

ACRS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.05 - $5.17

Previous CloseN/A

Volume227.82K

Average Volume (3M)930.55K

Market Cap

$199.33M

Enterprise Value$76.62M

Total Cash (Recent Filing)$99.81M

Total Debt (Recent Filing)$2.37M

Price to Earnings (P/E)―

Beta1.34

Next Earnings

Nov 05, 2025

EPS Estimate

-0.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding108,332,214

10 Day Avg. Volume1,073,770

30 Day Avg. Volume930,551

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.38

Enterprise Value/Revenue4.56

Enterprise Value/Gross Profit18.88

Enterprise Value/Ebitda-1.36

Forecast

1Y Price Target

$9.20

Price Target Upside394.62% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentATI-2138 clinical proof-of-concept data looks promising, providing evidence that the drug can offer efficacy comparable to approved treatments with improved tolerability.

Growth OpportunitiesAclaris Therapeutics intends to further develop ATI-2138 for alopecia areata and explore other indications, suggesting potential future growth opportunities.

Safety ProfileThe favorable safety profile of ATI-2138, if sustained, is expected to provide a key competitive advantage against approved JAK inhibitors.

Bears Say

Potential ConflictsInvestors should be aware of potential conflicts of interest as Wedbush Securities seeks to do business with companies covered in its research reports.

Study Design ConcernsCompared to the atopic dermatitis clinical landscape, '2138's treatment effect is competitive, though the study's design and sample size are noted.

Aclaris Therapeutics News

Aclaris Therapeutics to host R&D Day on October 14

Aclaris Therapeutics (ACRS) will host it’s 2025 R&D Day in Midtown, New York on Tuesday, October 14, 2025...

4d ago

ACRS

Promising Phase 2a Results and Strategic Expansion Drive Buy Rating for Aclaris Therapeutics

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Aclaris Therapeutics. The associated price target...

1M ago

ACRS

Aclaris Therapeutics Reports Q2 2025 Results and Updates

Aclaris Therapeutics Inc. ( ($ACRS) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

ACRS

Aclaris Therapeutics reports Q2 EPS (13c), consensus (13c)

Reports Q2 revenue $1.78M, consensus $1.29M. As of June 30, 2025, Aclaris had cash, cash equivalents and marketable...

2M ago

ACRS

Positive Outlook for Aclaris Therapeutics Driven by Promising Trial Results and Pipeline Advancements

Thomas Smith, an analyst from Leerink Partners, maintained the Buy rating on Aclaris Therapeutics. The associated price target...

2M ago

ACRS

Closing Bell Movers: Qorvo, Starbucks jump after quarterly reports

In the early hours of the evening session, U.S. equity futures were broadly lower, continuing the regular sessions...

2M ago

CAR

Aclaris announces ATI-2138 trial meets primary, secondary endpoints

Aclaris Therapeutics (ACRS) announced top-line results from its open-label, single-arm Phase 2a trial of ATI-2138 in 14 patients...

2M ago

ACRS

Aclaris Therapeutics Announces Positive Phase 2a Trial Results

Aclaris Therapeutics ( ($ACRS) ) just unveiled an update. On July 29, 2025, Aclaris Therapeutics announced the top-line...

2M ago

ACRS

Aclaris Therapeutics CSO Joe Monahan to retire, Roland Kolbeck to succeed

Aclaris Therapeutics (ACRS) announced that Roland Kolbeck, Ph.D. has been appointed as Chief Scientific Officer, replacing Joe Monahan,...

2M ago

ACRS

Aclaris Therapeutics assumed with an Overweight at Piper Sandler

Piper Sandler analyst Biren Amin assumed coverage of Aclaris Therapeutics (ACRS) with an Overweight rating and $6 price...

3M ago

ACRS

Aclaris Therapeutics Highlights Clinical Pipeline and Outlook

Aclaris Therapeutics ( ($ACRS) ) has provided an update. On June 30, 2025, Aclaris Therapeutics updated its corporate...

3M ago

ACRS

Aclaris Therapeutics: Promising Pipeline and Strategic Trials Justify Buy Rating

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Aclaris Therapeutics (ACRS – Research Report)....

3M ago

ACRS

Aclaris Therapeutics initiates Phase 1a/1b program for ATI-052

Aclaris Therapeutics (ACRS) has initiated a placebo-controlled Phase 1a/1b program for ATI-052, the Company’s potential best-in-class investigational bispecific...

3M ago

ACRS

Aclaris Therapeutics: Promising Pipeline and Strategic Advancements Support Buy Rating

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aclaris Therapeutics (ACRS – Research Report) today and...

4M ago

ACRS

ACRS FAQ

What was Aclaris Therapeutics Inc.’s price range in the past 12 months?

Aclaris Therapeutics Inc. lowest stock price was $1.05 and its highest was $5.17 in the past 12 months.

What is Aclaris Therapeutics Inc.’s market cap?

Aclaris Therapeutics Inc.’s market cap is $199.33M.

When is Aclaris Therapeutics Inc.’s upcoming earnings report date?

Aclaris Therapeutics Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 32 days.

How were Aclaris Therapeutics Inc.’s earnings last quarter?

Aclaris Therapeutics Inc. released its earnings results on Aug 06, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.133 by $0.003.

Is Aclaris Therapeutics Inc. overvalued?

According to Wall Street analysts Aclaris Therapeutics Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aclaris Therapeutics Inc. pay dividends?

Aclaris Therapeutics Inc. does not currently pay dividends.

What is Aclaris Therapeutics Inc.’s EPS estimate?

Aclaris Therapeutics Inc.’s EPS estimate is -0.13.

How many shares outstanding does Aclaris Therapeutics Inc. have?

Aclaris Therapeutics Inc. has 108,332,214 shares outstanding.

What happened to Aclaris Therapeutics Inc.’s price movement after its last earnings report?

Aclaris Therapeutics Inc. reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.133. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Aclaris Therapeutics Inc.?

Currently, no hedge funds are holding shares in ACRS

Aclaris Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-101.41%

Trailing 12-Months

Asset Growth

17.43%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aclaris Therapeutics Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological conditions and other diseases. The company specializes in novel treatments for skin disorders, particularly its lead product candidates aimed at conditions like alopecia areata and other inflammatory skin diseases. Aclaris leverages its proprietary technology platforms to advance its drug development pipeline, which includes both topical and systemic therapies.

Aclaris Therapeutics (ACRS) Earnings & Revenues

Historic Earnings Reports

ACRS Stock 12 Month Forecast

Average Price Target

$9.20

▲(394.62% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","17":"$17","4.25":"$4.25","8.5":"$8.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.25,8.5,12.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.99,3.0676923076923077,4.145384615384615,5.223076923076923,6.300769230769231,7.378461538461539,8.456153846153846,9.533846153846154,10.611538461538462,11.68923076923077,12.766923076923078,13.844615384615386,14.922307692307692,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.99,2.5446153846153843,3.0992307692307692,3.6538461538461533,4.208461538461538,4.763076923076922,5.317692307692307,5.872307692307691,6.426923076923076,6.981538461538461,7.536153846153845,8.09076923076923,8.645384615384614,{"y":9.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.99,2.2984615384615386,2.606923076923077,2.9153846153846152,3.2238461538461536,3.5323076923076924,3.8407692307692307,4.149230769230769,4.457692307692308,4.766153846153846,5.0746153846153845,5.383076923076923,5.691538461538461,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.32,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >